Open-Label, Phase 2a Pilot Study Evaluating the Efficacy and Tolerability of Topical Mesalamine Treatment in Adult Patients With Active Eosinophilic Esophagitis.
Thomas Greuter, Alex Straumann, Andrea Kreienbühl et al.
✦ AI-curated · Sources linked
In 30 seconds
This open-label, phase 2a pilot clinical trial evaluated the efficacy and tolerability of topical mesalamine in adults with active eosinophilic esophagitis (EoE). The supplied abstract describes EoE and the rationale for testing an additional treatment, noting that some patients are refractory or intolerant to available options. However, it provides no study results, participant numbers, treatment details, or quantitative outcomes, so the efficacy and tolerability findings cannot be summarized from the information provided.
Key findings
- The study was an open-label, phase 2a pilot trial of topical mesalamine in adults with active EoE.
- The supplied abstract reports no efficacy, tolerability, or safety results.
Why it matters
EoE is a chronic inflammatory esophageal disease, and the abstract identifies unmet need among patients who do not tolerate or respond to available treatments. Evaluating an agent with a different mode of action could be relevant to this gap, but the provided text does not establish whether mesalamine was effective or well tolerated.
What to keep in mind
The supplied abstract contains background and rationale only; it does not report the trial methods beyond its design or any results.